CD150-mediated AKT signalling pathway in normal and malignant B cells

Experimental Oncology

Volumn 33, Issue 1, 2011, Pages 9-18

  Yurchenko, M ^a   Shlapatska, L M ^a   Romanets, O L ^a   Ganshevskiy, D ^a   Kashuba, E ^a,b   Zamoshnikova, A ^a   Ushenin, Yu V ^c   Snopok, B A ^c   Sidorenko, S P ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

^b KAROLINSKA INSTITUTE   (Sweden)

^c INSTITUTE OF SEMICONDUCTOR PHYSICS   (Ukraine)

Author keywords

Akt; CD150 receptor; FoxO1; GSK 3 ; Hodgkin's lymphoma; Immortalized B cells; PI3 kinase

Indexed keywords

CD150 ANTIGEN; CD40 ANTIGEN; CELL EXTRACT; COMPLEMENTARY DNA; HYBRID PROTEIN; IMMUNOGLOBULIN M; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P85; PROTEIN P85 ALPHA; PROTEIN SERINE THREONINE KINASE; PROTEIN SUBUNIT; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; B LYMPHOCYTE; CELL IMMORTALIZATION; CELL ISOLATION; CELL STRAIN; CELL STRAIN L1236; CELL STRAIN LCL MP1; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOPLASM; DAUDI CELL; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LYMPHOMA; LYMPHOMA CELL LINE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE; TONSIL CELL; UPREGULATION; WESTERN BLOTTING;

ANTIGENS, CD; B-LYMPHOCYTES; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; HODGKIN DISEASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; INTRACELLULAR SPACE; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS;

EID: 78650693019     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Sidorenko SP, Clark EA. Characterization of a cell surface glycoprotein IPO-3, expressed on activated human B and T lymphocytes. J Immunol 1993; 151: 4614-24. (Pubitemid 23318515)
2. Wang N, Morra M, Wu C, et al. CD150 is a member of a family of genes that encode glycoproteins on the surface of hematopoietic cells. Immunogenetics 2001; 53: 382-94. (Pubitemid 32762815)
3. Sidorenko SP, Clark EA. The dual-function CD150 receptor subfamily: the viral attraction. Nat Immunol 2003; 4: 19-24. (Pubitemid 36104703)
4. Veillette A, Latour S. The SLAM family of immune-cell receptors. Curr Opin Immunol 2003; 15: 277-85. (Pubitemid 36645103)
5. Ostrakhovitch EA, Li SS. The role of SLAM family receptors in immune cell signaling. Biochem Cell Biol 2006; 84: 832-43. (Pubitemid 46450684)
6. Engel P, Eck MJ, Terhorst C. The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease. Nat Rev Immunol 2003; 3: 813-21. (Pubitemid 37328659)
7. Nanda N, Andre P, Bao M, et al. Platelet aggregation induces platelet aggregate stability via SLAM family receptor signaling. Blood 2005; 106: 3028-34. (Pubitemid 41565895)
8. Romero X, Benitez D, March S, et al. Differential expression of SAP and EAT-2-binding leukocyte cell-surface molecules CD84, CD150 (SLAM), CD229 (Ly9) and CD244 (2B4). Tissue Antigens 2004; 64: 132-44.
9. Yurchenko M, Sidorenko SP. Signaling Gateway Molecule Page CD150. UCSD-Nature Molecule Pages 2009; doi:10.1038/mp.a000905.01.
10. Mikhalap SV, Shlapatska LM, Yurchenko OV, et al. The adaptor protein SH2D1A regulates signaling through CD150 (SLAM) in B cells. Blood 2004; 104: 4063-70. (Pubitemid 39620157)
11. Shlapatska LM, Mikhalap SV, Berdova AG, et al. CD150 association with either the SH2-containing inositol phosphatase or the SH2-containing protein tyrosine phosphatase is regulated by the adaptor protein SH2D1A. J Immunol 2001; 166: 5480-7. (Pubitemid 32374169)
12. Yurchenko OV, Shlapatska LM, Skryma MR, et al. Immunohistochemical studies of CD150 expression in some human tumors. Exp Oncol 2003; 25: 186-190.
13. Brauninger A, Schmitz R, Bechtel D, et al. Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma. Int J Cancer 2006; 118: 1853-61.
14. Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009; 9: 15-27.
15. Schmitz R, Stanelle J, Hansmann ML, et al. Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annu Rev Pathol 2009; 4: 151-74.
16. Weniger MA, Melzner I, Menz CK, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 2006; 25: 2679-84.
17. Zheng B, Fiumara P, Li YV, et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 2003; 102: 1019-27.
18. Yurchenko MY, Kovalevska LM, Shlapatska LM, et al. CD150 regulates JNK1/2 activation in normal and Hodgkin's lymphoma B cells. Immunol Cell Biol 2010; 88: 565-74.
19. Georgakis GV, Li Y, Rassidakis GZ, et al. Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol 2006; 132: 503-11. (Pubitemid 43381621)
20. Dawson CW, Tramountanis G, Eliopoulos AG, et al. Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling. J Biol Chem 2003; 278: 3694-704. (Pubitemid 36801094)
21. Morrison JA, Gulley ML, Pathmanathan R, et al. Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma. Cancer Res 2004; 64: 5251-60. (Pubitemid 39006545)
22. Swart R, Ruf IK, Sample J, et al. Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway. J Virol 2000; 74: 10838-45.
23. Yurchenko M, Sidorenko SP. Hodgkin's lymphoma: the role of cell surface receptors in regulation of tumor cell fate. Exp Oncol 2010; 32: 214-23.
24. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010; 28: 1075-83.
25. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002; 14: 381-95. (Pubitemid 34214843)
26. Donahue AC, Fruman DA. PI3K signaling controls cell fate at many points in B lymphocyte development and activation. Semin Cell Dev Biol 2004; 15: 183-97. (Pubitemid 38251647)
27. Mikhalap SV, Shlapatska LM, Berdova AG, et al. CDw150 associates with src-homology 2-containing inositol phosphatase and modulates CD95-mediated apoptosis. J Immunol 1999; 162: 5719-27. (Pubitemid 29314922)
28. Yurchenko MY, Kashuba EV, Shlapatska LM, et al. The role of CD150-SH2D1A association in CD150 signaling in Hodgkin's lymphoma cell lines. Exp Oncol 2005; 27: 24-30. (Pubitemid 40547657)
29. Clark EA, Shu GL, Luscher B, et al. Activation of human B cells. Comparison of the signal transduced by IL-4 to four different competence signals. J Immunol 1989; 143: 3873-80. (Pubitemid 20012567)
30. Boltovets PM, Snopok BA, Boyko VR, et al. Detection of plant viruses using a surface plasmon resonance via complexing with specific antibodies. J Virol Methods 2004; 121: 101-6. (Pubitemid 39180031)
31. Snopok B, Yurchenko M, Szekely L, et al. SPR-based immunocapture approach to creating an interfacial sensing architecture: Mapping of the MRS18-2 binding site on retinoblastoma protein. Anal Bioanal Chem 2006; 386: 2063-73.
32. Boltovets PM, Savchenko AA, Snopok BA. Nanostructured interfacial architectures for detection of biospecific interactions. In: Optical Sensing Technology and Applications. Baldini F, Homola J, Lieberman RA, Miler M, eds. Bellingham: SPIE, 2007. 664 p.
33. Aoukaty A, Tan R. Association of the XLP gene product SAP/SH2D1A with 2B4, a natural killer cell activating molecule, is dependent on phosphoinositide 3-kinase. J Biol Chem 2002; 277: 13331-7. (Pubitemid 34952705)
34. Hu P, Margolis B, Skolnik EY, et al. Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors. Mol Cell Biol 1992; 12: 981-90.
35. Howie D, Simarro M, Sayos J, et al. Molecular dissection of the signaling and costimulatory functions of CD150 (SLAM): CD150/SAP binding and CD150-mediated costimulation. Blood 2002; 99: 957-65. (Pubitemid 34525558)
36. Latour S, Roncagalli R, Chen R, et al. Binding of SAP SH2 domain to FynT SH3 domain reveals a novel mechanism of receptor signaling in immune regulation. Nat Cell Biol 2003; 5: 149-54. (Pubitemid 36204197)
37. Li C, Iosef C, Jia CY, et al. Dual functional roles for the X-linked lymphoproliferative syndrome gene product SAP/SH2D1A in signaling through the signaling lymphocyte activation molecule (SLAM) family of immune receptors. J Biol Chem 2003; 278: 3852-9. (Pubitemid 36801114)
38. Astoul E, Watton S, Cantrell D. The dynamics of protein kinase B regulation during B cell antigen receptor engagement. J Cell Biol 1999; 145: 1511-20. (Pubitemid 29310007)
39. Cross DA, Alessi DR, Cohen P, et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785-9. (Pubitemid 26004411)
40. van der Horst A, Burgering BM. Stressing the role of FoxO proteins in lifespan and disease. Nat Rev Mol Cell Biol 2007; 8: 440-50. (Pubitemid 46809159)
41. Biggs WH 3rd, Meisenhelder J, Hunter T, et al. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci U S A 1999; 96: 7421-6. (Pubitemid 29299677)
42. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96: 857-68. (Pubitemid 29165088)
43. Matsuzaki H, Daitoku H, Hatta M, et al. Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc Natl Acad Sci U S A 2003; 100: 11285-90. (Pubitemid 37205927)
44. Dutton A, Reynolds GM, Dawson CW, et al. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol 2005; 205: 498-506. (Pubitemid 40361339)
45. Chan B, Lanyi A, Song HK, et al. SAP couples Fyn to SLAM immune receptors. Nat Cell Biol 2003; 5: 155-60. (Pubitemid 36204198)
46. Diehl JA, Cheng M, Roussel MF, et al. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998; 12: 3499-511. (Pubitemid 28553242)
47. Gregory MA, Qi Y, Hann SR. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem 2003; 278: 51606-12. (Pubitemid 38020405)
48. Yusuf I, Zhu X, Kharas MG, et al. Optimal B-cell proliferation requires phosphoinositide 3-kinase-dependent inactivation of FOXO transcription factors. Blood 2004; 104: 784-7. (Pubitemid 38970574)
49. Jonsson H, Peng SL. Forkhead transcription factors in immunology. Cell Mol Life Sci 2005; 62: 397-409. (Pubitemid 40379232)
50. Vogt PK, Jiang H, Aoki M. Triple layer control: phosphorylation, acetylation and ubiquitination of FOXO proteins. Cell Cycle 2005; 4: 908-13. (Pubitemid 41359756)
51. Essers MA, Weijzen S, de Vries-Smits AM, et al. FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. Embo J 2004; 23: 4802-12. (Pubitemid 40069710)
52. Sunayama J, Tsuruta F, Masuyama N, et al. JNK antagonizes Akt-mediated survival signals by phosphorylating 14-3-3. J Cell Biol 2005; 170: 295-304. (Pubitemid 41043811)
53. Meier R, Alessi DR, Cron P, et al. Mitogenic activation, phosphorylation, and nuclear translocation of protein kinase Bbeta. J Biol Chem 1997; 272: 30491-7. (Pubitemid 27512261)